---
title: Genetic Disorders
order: 5
category: Pathology
status: complete
last_updated: '2025-01-09'
---

# Genetic Disorders

## Overview

Genetic disorders are diseases caused by abnormalities in an individual's genetic material (DNA). These disorders can result from mutations in single genes, chromosomal abnormalities, or complex interactions between multiple genes and environmental factors. Understanding genetic disorders is crucial for diagnosis, treatment, genetic counseling, and prevention.

### Classification of Genetic Disorders
- **Single gene disorders (Mendelian)**: Mutations in individual genes
- **Chromosomal disorders**: Numerical or structural chromosome abnormalities
- **Complex genetic disorders**: Multiple genes with environmental factors
- **Mitochondrial disorders**: Mutations in mitochondrial DNA

## Single Gene Disorders

### Autosomal Dominant Disorders

#### Characteristics
- **Inheritance pattern**: One mutated copy causes disease
- **Penetrance**: May be incomplete (not all carriers affected)
- **Expressivity**: Variable severity among affected individuals
- **De novo mutations**: ~50% of cases may be new mutations

#### Examples

##### Huntington Disease
- **Gene**: HTT gene on chromosome 4
- **Mutation**: CAG trinucleotide repeat expansion
- **Pathophysiology**: Huntingtin protein aggregation, neurodegeneration
- **Clinical features**: Progressive chorea, dementia, psychiatric symptoms
- **Onset**: Typically 30-50 years
- **Anticipation**: Earlier onset with paternal transmission

##### Familial Hypercholesterolemia
- **Gene**: LDLR, APOB, PCSK9
- **Pathophysiology**: Defective LDL receptor function
- **Clinical features**: Severe hypercholesterolemia, premature atherosclerosis
- **Physical signs**: Tendon xanthomas, corneal arcus
- **Treatment**: Statins, PCSK9 inhibitors, LDL apheresis

##### Marfan Syndrome
- **Gene**: FBN1 (fibrillin-1)
- **Pathophysiology**: Connective tissue defect
- **Clinical features**: Tall stature, arachnodactyly, lens dislocation, aortic dilation
- **Complications**: Aortic dissection, mitral valve prolapse
- **Management**: Cardiac monitoring, activity restrictions

##### Neurofibromatosis Type 1
- **Gene**: NF1 (neurofibromin)
- **Pathophysiology**: Tumor suppressor gene loss
- **Clinical features**: Café-au-lait spots, neurofibromas, learning disabilities
- **Complications**: Malignant transformation, optic gliomas
- **Surveillance**: Regular ophthalmologic and neurologic examinations

### Autosomal Recessive Disorders

#### Characteristics
- **Inheritance pattern**: Two mutated copies required for disease
- **Carrier frequency**: Higher in consanguineous populations
- **Clinical presentation**: Often severe, early onset
- **Enzyme deficiencies**: Many involve metabolic pathways

#### Examples

##### Cystic Fibrosis
- **Gene**: CFTR (cystic fibrosis transmembrane conductance regulator)
- **Pathophysiology**: Defective chloride transport
- **Clinical features**: Chronic lung disease, pancreatic insufficiency, elevated sweat chloride
- **Complications**: Bronchiectasis, diabetes, infertility
- **Treatment**: Airway clearance, CFTR modulators, lung transplantation

##### Sickle Cell Disease
- **Gene**: HBB (β-globin)
- **Mutation**: Glu6Val substitution (HbS)
- **Pathophysiology**: Hemoglobin polymerization, red cell sickling
- **Clinical features**: Vaso-occlusive crises, chronic anemia, organ damage
- **Complications**: Stroke, acute chest syndrome, splenic sequestration
- **Treatment**: Hydroxyurea, blood transfusions, bone marrow transplant

##### Tay-Sachs Disease
- **Gene**: HEXA (β-hexosaminidase A)
- **Pathophysiology**: GM2 ganglioside accumulation
- **Clinical features**: Progressive neurodegeneration, cherry-red macula
- **Onset**: Infantile form most severe
- **Prognosis**: Fatal by 2-4 years
- **Prevention**: Carrier screening in high-risk populations

##### Phenylketonuria (PKU)
- **Gene**: PAH (phenylalanine hydroxylase)
- **Pathophysiology**: Phenylalanine accumulation
- **Clinical features**: Intellectual disability, seizures, light pigmentation
- **Treatment**: Phenylalanine-restricted diet
- **Screening**: Newborn screening programs
- **Prognosis**: Normal development with early treatment

### X-Linked Disorders

#### Characteristics
- **Inheritance pattern**: Gene located on X chromosome
- **Male expression**: Hemizygous males more severely affected
- **Female carriers**: May have mild symptoms due to X-inactivation
- **Transmission**: No male-to-male transmission

#### Examples

##### Duchenne Muscular Dystrophy
- **Gene**: DMD (dystrophin)
- **Pathophysiology**: Absent or defective dystrophin protein
- **Clinical features**: Progressive muscle weakness, cardiomyopathy
- **Onset**: Early childhood (2-5 years)
- **Complications**: Respiratory failure, cardiac arrhythmias
- **Treatment**: Corticosteroids, supportive care, gene therapy trials

##### Hemophilia A
- **Gene**: F8 (factor VIII)
- **Pathophysiology**: Coagulation factor deficiency
- **Clinical features**: Bleeding episodes, hemarthroses
- **Severity**: Mild, moderate, or severe based on factor levels
- **Treatment**: Factor VIII replacement, desmopressin
- **Complications**: Inhibitor development, arthropathy

##### Fragile X Syndrome
- **Gene**: FMR1 (fragile X mental retardation 1)
- **Mutation**: CGG repeat expansion
- **Pathophysiology**: FMRP protein deficiency
- **Clinical features**: Intellectual disability, autism spectrum behaviors
- **Physical features**: Large ears, long face, macroorchidism
- **Treatment**: Behavioral interventions, symptomatic therapy

## Chromosomal Disorders

### Numerical Abnormalities

#### Autosomal Trisomies

##### Down Syndrome (Trisomy 21)
- **Incidence**: 1 in 700-800 births
- **Risk factors**: Advanced maternal age
- **Clinical features**: Intellectual disability, characteristic facies, cardiac defects
- **Associated conditions**: Alzheimer disease, leukemia, hypothyroidism
- **Life expectancy**: ~60 years with appropriate care

##### Edwards Syndrome (Trisomy 18)
- **Incidence**: 1 in 5,000 births
- **Clinical features**: Severe intellectual disability, multiple malformations
- **Prognosis**: Most die within first year
- **Prenatal diagnosis**: Often detected by ultrasound

##### Patau Syndrome (Trisomy 13)
- **Incidence**: 1 in 16,000 births
- **Clinical features**: Severe intellectual disability, holoprosencephaly, cleft lip/palate
- **Prognosis**: Most die within first year
- **Associated defects**: Cardiac, renal, CNS malformations

#### Sex Chromosome Abnormalities

##### Turner Syndrome (45,X)
- **Incidence**: 1 in 2,500 female births
- **Clinical features**: Short stature, infertility, webbed neck, cardiac defects
- **Associated conditions**: Kidney abnormalities, hearing loss, learning disabilities
- **Treatment**: Growth hormone, estrogen replacement

##### Klinefelter Syndrome (47,XXY)
- **Incidence**: 1 in 650 male births
- **Clinical features**: Tall stature, small testes, gynecomastia, infertility
- **Associated conditions**: Learning disabilities, osteoporosis
- **Treatment**: Testosterone replacement therapy

### Structural Abnormalities

#### Deletions
- **22q11.2 deletion syndrome**: DiGeorge syndrome, cardiac defects, immunodeficiency
- **Williams syndrome**: 7q11.23 deletion, supravalvular aortic stenosis
- **Prader-Willi syndrome**: 15q11-q13 paternal deletion, hypotonia, obesity
- **Angelman syndrome**: 15q11-q13 maternal deletion, severe intellectual disability

#### Duplications
- **Charcot-Marie-Tooth disease**: PMP22 duplication, peripheral neuropathy
- **Pelizaeus-Merzbacher disease**: PLP1 duplication, dysmyelination

#### Translocations
- **Chronic myeloid leukemia**: t(9;22) Philadelphia chromosome
- **Burkitt lymphoma**: t(8;14) MYC-IGH translocation

## Complex Genetic Disorders

### Multifactorial Inheritance
- **Definition**: Multiple genes plus environmental factors
- **Examples**: Diabetes, hypertension, coronary artery disease, schizophrenia
- **Characteristics**: Familial clustering, threshold effect, variable expression
- **Risk assessment**: Polygenic risk scores

### Common Complex Disorders

#### Type 2 Diabetes
- **Heritability**: ~40-70%
- **Risk genes**: TCF7L2, PPARG, KCNJ11, others
- **Environmental factors**: Obesity, physical inactivity, diet
- **Prevention**: Lifestyle modifications

#### Coronary Artery Disease
- **Heritability**: ~40-50%
- **Risk genes**: PCSK9, LDLR, APOE, others
- **Environmental factors**: Smoking, diet, exercise
- **Prevention**: Risk factor modification

#### Autism Spectrum Disorders
- **Heritability**: >80%
- **Risk genes**: Hundreds identified (SHANK3, CHD8, SCN2A)
- **Environmental factors**: Advanced parental age, prenatal infections
- **Heterogeneity**: Highly variable clinical presentation

## Mitochondrial Disorders

### Characteristics
- **Inheritance**: Maternal inheritance (mtDNA)
- **Heteroplasmy**: Variable proportion of mutated mtDNA
- **Tissue specificity**: Affects high-energy tissues (brain, muscle, heart)
- **Clinical features**: Progressive, multisystem involvement

### Examples

#### MELAS Syndrome
- **Definition**: Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes
- **Mutation**: Usually A3243G in tRNA(Leu)
- **Clinical features**: Seizures, dementia, muscle weakness
- **Diagnosis**: Muscle biopsy, genetic testing

#### Leber Hereditary Optic Neuropathy
- **Mutations**: G11778A, G3460A, T14484C
- **Clinical features**: Acute/subacute bilateral optic neuropathy
- **Demographics**: More common in males
- **Prognosis**: Variable visual recovery

## Diagnostic Approaches

### Clinical Assessment
- **Family history**: Three-generation pedigree
- **Physical examination**: Dysmorphic features, growth parameters
- **Developmental assessment**: Cognitive and motor milestones
- **System review**: Multi-organ involvement patterns

### Laboratory Testing

#### Chromosomal Analysis
- **Karyotype**: Standard G-banded analysis
- **FISH**: Fluorescence in situ hybridization for specific regions
- **Chromosomal microarray**: High-resolution copy number analysis
- **Optical genome mapping**: Ultra-high resolution structural variant detection

#### Molecular Genetic Testing
- **Single gene testing**: Targeted mutation analysis
- **Gene panels**: Multiple genes for specific conditions
- **Exome sequencing**: All protein-coding regions
- **Genome sequencing**: Complete genomic sequence

#### Biochemical Testing
- **Enzyme assays**: Specific enzyme deficiencies
- **Metabolite analysis**: Amino acids, organic acids, fatty acids
- **Biomarkers**: Disease-specific molecules

### Prenatal Diagnosis
- **Maternal serum screening**: Down syndrome, neural tube defects
- **Cell-free DNA**: Non-invasive prenatal testing
- **Chorionic villus sampling**: First trimester tissue sampling
- **Amniocentesis**: Second trimester fluid sampling

### Preimplantation Genetic Diagnosis
- **In vitro fertilization**: With embryo genetic testing
- **Single cell analysis**: Polar body or blastomere biopsy
- **Monogenic disorders**: Known familial mutations
- **Chromosomal abnormalities**: Aneuploidy screening

## Treatment and Management

### Therapeutic Approaches

#### Enzyme Replacement Therapy
- **Gaucher disease**: Glucocerebrosidase replacement
- **Pompe disease**: α-glucosidase replacement
- **Fabry disease**: α-galactosidase replacement
- **MPS disorders**: Various enzyme replacements

#### Substrate Reduction Therapy
- **Gaucher disease**: Miglustat, eliglustat
- **Niemann-Pick disease**: Miglustat
- **Mechanism**: Reduces substrate accumulation

#### Gene Therapy
- **Severe combined immunodeficiency**: ADA-SCID, X-SCID
- **Leber congenital amaurosis**: RPE65 gene replacement
- **Spinal muscular atrophy**: SMN1 gene replacement
- **Challenges**: Delivery, immunogenicity, durability

#### Small Molecule Therapy
- **Cystic fibrosis**: CFTR modulators (ivacaftor, lumacaftor)
- **Duchenne MD**: Ataluren for nonsense mutations
- **Spinal muscular atrophy**: Spinraza (antisense oligonucleotide)

### Supportive Care
- **Multidisciplinary teams**: Specialized clinics
- **Symptomatic treatment**: Managing complications
- **Rehabilitation**: Physical, occupational, speech therapy
- **Nutritional support**: Specialized diets, supplements

### Genetic Counseling
- **Risk assessment**: Recurrence risks, carrier status
- **Education**: Disease information, inheritance patterns
- **Psychosocial support**: Coping strategies, family dynamics
- **Reproductive options**: Prenatal diagnosis, assisted reproduction

## Prevention and Screening

### Primary Prevention
- **Folic acid supplementation**: Neural tube defect prevention
- **Carrier screening**: Tay-Sachs, cystic fibrosis, sickle cell
- **Genetic counseling**: Family planning decisions
- **Lifestyle modifications**: Environmental risk factors

### Secondary Prevention
- **Newborn screening**: PKU, hypothyroidism, SCID, SMA
- **Cascade screening**: Family members of affected individuals
- **Presymptomatic testing**: Huntington disease, BRCA mutations
- **Early intervention**: Developmental support services

### Population Screening
- **Carrier screening programs**: Ashkenazi Jewish, Mediterranean populations
- **Expanded newborn screening**: 30+ conditions in many countries
- **Pharmacogenomics**: Drug metabolism variants
- **Cancer predisposition**: BRCA1/2, Lynch syndrome

## Ethical Considerations

### Genetic Testing
- **Informed consent**: Understanding implications
- **Confidentiality**: Genetic information protection
- **Discrimination**: Insurance, employment concerns
- **Incidental findings**: Unexpected test results

### Reproductive Decisions
- **Autonomous choice**: Individual decision-making
- **Prenatal testing**: Termination decisions
- **Preimplantation diagnosis**: Embryo selection
- **Genetic enhancement**: Future considerations

### Research Ethics
- **Benefit sharing**: Community involvement
- **Vulnerable populations**: Special protections
- **Data sharing**: Privacy vs. scientific benefit
- **Return of results**: Research vs. clinical findings

## Future Directions

### Precision Medicine
- **Pharmacogenomics**: Personalized drug therapy
- **Polygenic risk scores**: Disease risk prediction
- **Multi-omics**: Integration of genomic data types
- **Artificial intelligence**: Pattern recognition, diagnosis

### Therapeutic Advances
- **Gene editing**: CRISPR-Cas9 applications
- **Base editing**: Precise nucleotide changes
- **Prime editing**: Targeted insertions, deletions
- **Epigenome editing**: Modifying gene expression

### Global Health
- **Health equity**: Access to genetic services
- **Genomic diversity**: Representation in research
- **Capacity building**: Training, infrastructure
- **Cost reduction**: Affordable testing, treatment

## Key Points

- Genetic disorders result from DNA mutations and can be single gene, chromosomal, or complex
- Inheritance patterns include autosomal dominant/recessive, X-linked, and mitochondrial
- Common single gene disorders include cystic fibrosis, sickle cell disease, and Huntington disease
- Chromosomal disorders include numerical (trisomies) and structural abnormalities
- Complex disorders involve multiple genes and environmental factors
- Diagnosis uses clinical assessment, chromosomal analysis, and molecular testing
- Treatment options include enzyme replacement, gene therapy, and supportive care
- Genetic counseling provides risk assessment, education, and psychosocial support
- Prevention strategies include carrier screening, newborn screening, and genetic counseling
- Ethical considerations include consent, confidentiality, and reproductive autonomy

## References

1. Nussbaum RL, McInnes RR, Willard HF. Thompson & Thompson Genetics in Medicine. 8th ed. Elsevier; 2015.
2. Rimoin DL, Pyeritz RE, Korf BR. Emery and Rimoin's Principles and Practice of Medical Genetics. 6th ed. Academic Press; 2013.
3. Online Mendelian Inheritance in Man (OMIM). McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University. Available at: https://omim.org/
